<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413972</url>
  </required_header>
  <id_info>
    <org_study_id>P04420</org_study_id>
    <secondary_id>SCH 465981</secondary_id>
    <nct_id>NCT00413972</nct_id>
  </id_info>
  <brief_title>Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Groups Study Comparing the Efficacy and Safety of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 3
      study of Vytorin 10/10 (ezetimibe 10 mg with simvastatin 10 mg), Vytorin 10/20 (ezetimibe 10
      mg with simvastatin 20 mg), and Vytorin 10/40 (ezetimibe 10 mg with simvastatin 40 mg)
      compared to placebo administered daily for 8 consecutive weeks in subjects with primary
      hypercholesterolemia (LDL-C &gt;3.64 mmol/L [140 mg/dL]). The efficacy of daily Vytorin versus
      placebo in reducing the concentration of LDL-C will be evaluated, and the efficacy of daily
      Vytorin versus placebo with respect to change in the concentrations of total cholesterol,
      triglycerides, and HDL-C will be compared. The safety of Vytorin versus placebo will also be
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Vytorin 10/10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe 10 mg with Simvastatin 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vytorin 10/20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe 10 mg with Simvastatin 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vytorin 10/40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe 10 mg with Simvastatin 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe with simvastatin</intervention_name>
    <description>Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks</description>
    <arm_group_label>Vytorin 10/10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe with Simvastatin</intervention_name>
    <description>Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks</description>
    <arm_group_label>Vytorin 10/20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe with Simvastatin</intervention_name>
    <description>Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks</description>
    <arm_group_label>Vytorin 10/40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for a total of eight weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be &gt;=18 years and &lt;=75 years of age, male or female.

          -  Primary hypercholesterolemic subject with a plasma LDL cholesterol concentration &gt;3.64
             mmol/L (140 mg/dL) to &lt;=6.3 mmol/L (250 mg/dL) using the Friedewald calculation; total
             cholesterol (TC) &gt;5.2 mmol/L (200 mg/dL) to &lt;12.7 mmol/L (500 mg/dL) and triglyceride
             concentrations of &lt;=3.99 mmol/L (350 mg/dL) should be met at the same time. At the
             time of recruitment (Visit 1), these values may be lower if the subject is on
             lipid-lowering therapy. (ie, prior to the start of lipid lowering drug washout) or may
             be higher at the start of dietary therapy.

          -  Liver transaminases (ALT, AST) &lt;=50% above the upper limit of normal, with no active
             liver disease and CK &lt;=50% above the upper limit of normal.

          -  Clinical laboratory tests (complete blood count [CBC], blood chemistries, urinalysis)
             must be within normal limits, or clinically acceptable to the investigator/sponsor.

          -  Women of childbearing potential (includes women who are less than 1 year
             postmenopausal and women who become sexually active) must be using an acceptable
             method of birth control.

          -  Subjects must be free of any clinically significant diseases other than hyperlipidemia
             that would interfere with study evaluations.

          -  Subjects must understand and be able to adhere to the dosing and visit schedules.

          -  Subject must agree to remain on a cholesterol-lowering diet for the duration of the
             study (according to China Adult Treatment Panel of High Blood Cholesterol).

        Exclusion Criteria:

          -  Subjects whose body mass index (BMI=weight [kg]/height2 [m]) is &gt;=30 kg/m2 at Visit 3
             (Baseline Visit).

          -  Subjects who have known hypersensitivity to HMG CoA reductase inhibitors.

          -  Subjects who consume &gt;14 alcoholic drinks per week. (A drink is: a can of beer, glass
             of wine, or single measure of spirits).

          -  Any condition or situation, which in the opinion of the investigator, might pose a
             risk to the subject or interfere with participation in the study.

          -  Women who are pregnant or nursing.

          -  Subjects who have not observed the designated washout periods for any of the
             prohibited medications.

          -  Congestive heart failure defined by NYHA as Class III or IV.

          -  Uncontrolled cardiac arrhythmia.

          -  Myocardial infarction, coronary bypass surgery, or angioplasty within 6 months of
             study entry.

          -  Unstable or severe peripheral artery disease within 3 months of study entry.

          -  Unstable angina pectoris within 6 months of study entry.

          -  Uncontrolled hypertension (treated or untreated) with systolic blood pressure &gt;160 mm
             Hg or diastolic &gt;100 mm Hg at study entry.

          -  Uncontrolled (as determined by fasting glucose &gt;180 mg/mL or HbA1c &gt;9%) or newly
             diagnosed (within 1 month of study entry) diabetes mellitus.

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins, ie, secondary causes of hyperlipidemia, such as secondary
             hypercholesterolemia due to hypothyroidism (thyroid stimulating hormone [TSH] above
             upper limit of normal). Subjects with a history of hypothyroidism who are on a stable
             therapy of thyroid hormone replacement for at least 6 weeks are eligible for
             enrollment if TSH levels are within normal limits before enrollment.

          -  Known impaired renal function (plasma creatinine &gt;2.0 mg/dL), or nephrotic syndrome at
             study entry.

          -  Disorders of the hematologic, digestive, or central nervous systems, including
             cerebrovascular disease and degenerative disease that would limit study evaluation or
             participation.

          -  Known HIV positive.

          -  Cancer within the past 5 years (except for successfully treated basal and squamous
             cell carcinomas).

          -  History of mental instability, drug/alcohol abuse within the past 5 years, or major
             psychiatric illness not adequately controlled and stable on pharmacotherapy.

          -  Female subject receiving hormonal therapy, including hormone replacement, any estrogen
             antagonist/agonist, or oral contraceptives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2006</study_first_submitted>
  <study_first_submitted_qc>December 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2006</study_first_posted>
  <results_first_submitted>April 28, 2010</results_first_submitted>
  <results_first_submitted_qc>April 28, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2010</results_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vytorin 10/10</title>
          <description>Ezetimibe 10 mg with Simvastatin 10 mg</description>
        </group>
        <group group_id="P2">
          <title>Vytorin 10/20</title>
          <description>Ezetimibe 10 mg with Simvastatin 20 mg</description>
        </group>
        <group group_id="P3">
          <title>Vytorin 10/40</title>
          <description>Ezetimibe 10 mg with Simvastatin 40 mg</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98">1 of the 98 randomized subjects was not treated and was excluded from the ITT data set.</participants>
                <participants group_id="P2" count="98">1 of the 98 randomized subjects was not treated and was excluded from the ITT data set.</participants>
                <participants group_id="P3" count="98"/>
                <participants group_id="P4" count="98">1 of the 98 randomized subjects was not treated and was excluded from the ITT data set.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vytorin 10/10</title>
          <description>Ezetimibe 10 mg with Simvastatin 10 mg</description>
        </group>
        <group group_id="B2">
          <title>Vytorin 10/20</title>
          <description>Ezetimibe 10 mg with Simvastatin 20 mg</description>
        </group>
        <group group_id="B3">
          <title>Vytorin 10/40</title>
          <description>Ezetimibe 10 mg with Simvastatin 40 mg</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="98"/>
            <count group_id="B4" value="97"/>
            <count group_id="B5" value="389"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="10.7"/>
                    <measurement group_id="B2" value="57.4" spread="9.7"/>
                    <measurement group_id="B3" value="56.4" spread="10.3"/>
                    <measurement group_id="B4" value="60.2" spread="9.2"/>
                    <measurement group_id="B5" value="58.2" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment</title>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>The number of participants for analysis included those from the ITT data set. 392 subjects were randomized in the study, but 3 of the randomized subjects were not treated and were excluded from the ITT data set. Therefore, only 389 subjects were included in the ITT data set.</population>
        <group_list>
          <group group_id="O1">
            <title>Vytorin 10/10</title>
            <description>Ezetimibe 10 mg with Simvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Vytorin 10/20</title>
            <description>Ezetimibe 10 mg with Simvastatin 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Vytorin 10/40</title>
            <description>Ezetimibe 10 mg with Simvastatin 40 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment</title>
          <population>The number of participants for analysis included those from the ITT data set. 392 subjects were randomized in the study, but 3 of the randomized subjects were not treated and were excluded from the ITT data set. Therefore, only 389 subjects were included in the ITT data set.</population>
          <units>percent change of LDL-C</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.69" spread="2.06"/>
                    <measurement group_id="O2" value="-46.83" spread="2.08"/>
                    <measurement group_id="O3" value="-49.10" spread="2.07"/>
                    <measurement group_id="O4" value="-7.53" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vytorin 10/10</title>
          <description>Ezetimibe 10 mg with Simvastatin 10 mg</description>
        </group>
        <group group_id="E2">
          <title>Vytorin 10/20</title>
          <description>Ezetimibe 10 mg with Simvastatin 20 mg</description>
        </group>
        <group group_id="E3">
          <title>Vytorin 10/40</title>
          <description>Ezetimibe 10 mg with Simvastatin 40 mg</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

